BPC-157 is not a first-line treatment for most conditions
Storage & Handling Store in a cool, dry environment away from direct light
Teva Pharmaceuticals launched the first authorized generic in the United States in June 2024, with Hikma receiving FDA approval for both generic Victoza and generic Saxenda in December 2024
Most reactions are mild and transient, resolving as your body adapts to replenished B12 levels
BPC-157 supports this interconnected system by: Strengthening tight junctions between intestinal epithelial cells, reducing intestinal permeability (leaky gut) Modulating the enteric nervous system to normalize motility and reduce visceral hypersensitivity Regulating mucosal immune responses to prevent inappropriate inflammation against dietary and microbial antigens Conditions Treated with Oral BPC-157 Beyond Symptom Relief: Addressing Root Causes Unlike proton pump inhibitors (PPIs) that suppress stomach acid or corticosteroids that broadly dampen immunity, BPC-157 works by restoring the underlying structural and functional integrity of the gastrointestinal tract
If you notice signs of anaphylaxisswelling of your tongue, face, or throat, difficulty breathing, or difficulty swallowingafter getting a B12 injection, call 911 or head to the closest emergency room immediately